Image For Activity Cover
Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies (JACC: CardioOncology June 2022-2)
Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies
The risk for major adverse cardiovascular events (MACE) with targeted therapies for patients with advanced renal cell carcinoma (RCC) in real-world practice remains unclear. The aim of this study was to compare the risk for MACE associated with targeted cancer therapies with that associated with cytokine treatment in patients with advanced RCC.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Authors
Dong-Yi Chen, MD
Wen-Kuan Huang, MD, PHD
Lai-Chu See, PHD

Important Dates

Date of Release: June 21, 2022
Term of Approval/Date of CME/MOC/ECME Expiration: June 20, 2023

Summary
Availability: On-Demand
Expires on Jun 20, 2023
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By